SUSRF (Surgical Science Sweden AB) Beneish M-Score: -2.54 (As of Jun. 26, 2026)


SUSRF Surgical Science Sweden AB SUSRF
82 GF Score
Price $4.00
GF Value $14.30
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Surgical Science Sweden AB Beneish M-Score?

Surgical Science Sweden AB SUSRF -2.20% 82 Beneish M-Score is -2.54 as of Jun. 26, 2026. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $14.30 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 633 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks worse than 54.66% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.54 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Surgical Science Sweden AB's Beneish M-Score or its related term are showing as below:

SUSRF' s Beneish M-Score Range Over the Past 10 Years
Min: -3.4   Med: -2.28   Max: 1.24
Current: -2.54

During the past 11 years, the highest Beneish M-Score of Surgical Science Sweden AB was 1.24. The lowest was -3.40. And the median was -2.28.


Surgical Science Sweden AB Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Surgical Science Sweden AB's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surgical Science Sweden AB Beneish M-Score Chart

Surgical Science Sweden AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 -1.60 -2.69 -2.50 -2.22

Surgical Science Sweden AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.17 -2.30 -2.27 -2.22 -2.54

SUSRF vs VEEV, BTSG, TEM: Beneish M-Score Comparison

For the Health Information Services subindustry, Surgical Science Sweden AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surgical Science Sweden AB Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Surgical Science Sweden AB's Beneish M-Score falls into.


SUSRF
82GF Score
Surgical Science Sweden AB SUSRF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Surgical Science Sweden AB Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Surgical Science Sweden AB for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.953+0.528 * 1.0441+0.404 * 0.9719+0.892 * 1.151+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9785+4.679 * -0.020235-0.327 * 0.9559
=-2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $33.4 Mil.
Revenue was 25.274 + 28.929 + 28.129 + 21.905 = $104.2 Mil.
Gross Profit was 16.633 + 19.18 + 18.184 + 14.285 = $68.3 Mil.
Total Current Assets was $127.4 Mil.
Total Assets was $515.6 Mil.
Property, Plant and Equipment(Net PPE) was $12.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.0 Mil.
Selling, General, & Admin. Expense(SGA) was $31.6 Mil.
Total Current Liabilities was $28.7 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Net Income was 1.999 + 3.578 + 2.177 + -2.103 = $5.7 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.0 Mil.
Cash Flow from Operations was 7.009 + 7.843 + -0.466 + 1.699 = $16.1 Mil.
Total Receivables was $30.5 Mil.
Revenue was 24.741 + 22.899 + 22.664 + 20.26 = $90.6 Mil.
Gross Profit was 17.034 + 15.482 + 15.741 + 13.682 = $61.9 Mil.
Total Current Assets was $109.5 Mil.
Total Assets was $483.3 Mil.
Property, Plant and Equipment(Net PPE) was $11.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.0 Mil.
Selling, General, & Admin. Expense(SGA) was $28.1 Mil.
Total Current Liabilities was $28.1 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(33.417 / 104.237) / (30.464 / 90.564)
=0.320587 / 0.336381
=0.953

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(61.939 / 90.564) / (68.282 / 104.237)
=0.683925 / 0.655065
=1.0441

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (127.354 + 12.067) / 515.631) / (1 - (109.492 + 11.002) / 483.296)
=0.729611 / 0.750683
=0.9719

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=104.237 / 90.564
=1.151

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 11.002)) / (0 / (0 + 12.067))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(31.647 / 104.237) / (28.101 / 90.564)
=0.303606 / 0.310289
=0.9785

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 28.701) / 515.631) / ((0 + 28.143) / 483.296)
=0.055662 / 0.058231
=0.9559

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(5.651 - 0 - 16.085) / 515.631
=-0.020235

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Surgical Science Sweden AB has a M-score of -2.45 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.54 mean?
Surgical Science Sweden AB (SUSRF) has a Beneish M-Score of -2.54 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Surgical Science Sweden AB and its competitors. According to the industry distribution chart, Surgical Science Sweden AB ranks #346 out of 633 companies in the Healthcare Providers & Services industry, placing it in the top 54.7%.
Is Surgical Science Sweden AB's Beneish M-Score too high?
Surgical Science Sweden AB's current Beneish M-Score is -2.54. Based on the distribution chart, Surgical Science Sweden AB ranks #346 out of 633 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Beneish M-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #346 out of 633 companies for Beneish M-Score. This places Surgical Science Sweden AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Surgical Science Sweden AB and its competitors. Surgical Science Sweden AB's current Beneish M-Score is -2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.30, compared to a current price of $4.00 — trading 72% below its estimated fair value. The current Beneish M-Score is -2.54. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Beneish M-Score is -2.54 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?

Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued. The current stock price of $4.00 is trading 72% below its estimated GF Value™ of $14.30. GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.

Key valuation signals for SUSRF:

  • Beneish M-Score: -2.54
  • GF Value™: $14.30 vs. price of $4.00 (72% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Surgical Science Sweden AB Business Description

Other Exchanges SUS:Sweden4P41:Germany
Address Drakegatan 7A, Gothenburg, SWE, SE-412 50
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score

Get the complete analysis for SUSRF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00
Price
$14.30
GF Value